| scholarly article | Q13442814 |
| P50 | author | Karin Rodland | Q90008917 |
| Andrew N Hoofnagle | Q87223570 | ||
| P2093 | author name string | Bing Zhang | |
| Amanda G Paulovich | |||
| Jeffrey R Whiteaker | |||
| Geoffrey S Baird | |||
| P2860 | cites work | Hallmarks of alternative splicing in cancer | Q38171229 |
| Alternative splicing in cancer: implications for biology and therapy | Q38179828 | ||
| MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum | Q38183147 | ||
| US Food and Drug Administration Perspectives on Clinical Mass Spectrometry. | Q38629381 | ||
| Identification of differentially expressed splice variants by the proteogenomic pipeline Splicify | Q38659439 | ||
| Proteogenomics from a bioinformatics angle: A growing field. | Q38670152 | ||
| Targeted proteomic assays for quantitation of proteins identified by proteogenomic analysis of ovarian cancer | Q38672374 | ||
| Proteogenomics for understanding oncology: recent advances and future prospects | Q38677257 | ||
| The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics | Q38686995 | ||
| Effects of calibration approaches on the accuracy for LC-MS targeted quantification of therapeutic protein | Q38699577 | ||
| Colorectal Cancer Cell Line Proteomes are Representative of Primary Tumors and Predict Drug Sensitivity | Q38699958 | ||
| Absolute Protein Quantification by Mass Spectrometry: Not as Simple as Advertised | Q38700574 | ||
| Proof of the quantitative potential of immunofluorescence by mass spectrometry | Q38721164 | ||
| Constrained selected reaction monitoring: quantification of selected post-translational modifications and protein isoforms | Q38806844 | ||
| Methods, Tools and Current Perspectives in Proteogenomics | Q38812665 | ||
| Parallel reaction monitoring using quadrupole-Orbitrap mass spectrometer: Principle and applications | Q38825316 | ||
| Mass spectrometry-based antigen discovery for cancer immunotherapy. | Q38828098 | ||
| Large-Scale SRM Screen of Urothelial Bladder Cancer Candidate Biomarkers in Urine | Q38911502 | ||
| Proteotypic Peptides and Their Applications | Q39099800 | ||
| Epigenetic plasticity and the hallmarks of cancer. | Q39448979 | ||
| Comprehensive Single-Shot Proteomics with FAIMS on a Hybrid Orbitrap Mass Spectrometer | Q89403024 | ||
| Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma | Q90290448 | ||
| Cancer genome landscapes | Q22242276 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Genome-wide epigenetic regulation of miRNAs in cancer | Q26863460 | ||
| miRNA Deregulation in Cancer Cells and the Tumor Microenvironment | Q27025496 | ||
| An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database | Q27861106 | ||
| Advances in targeted proteomics and applications to biomedical research | Q28066912 | ||
| Mass spectrometry-based proteomics | Q28182890 | ||
| Proteogenomic characterization of human colon and rectal cancer | Q28244320 | ||
| PhosphoSitePlus, 2014: mutations, PTMs and recalibrations | Q28254001 | ||
| Reverse phase protein microarrays advance to use in clinical trials | Q28384553 | ||
| Human SRMAtlas: A Resource of Targeted Assays to Quantify the Complete Human Proteome | Q28468274 | ||
| The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition | Q28584437 | ||
| Proteogenomics: concepts, applications and computational strategies | Q28649850 | ||
| Pathway and network analysis of cancer genomes | Q28914768 | ||
| Implementing Genome-Driven Oncology | Q30235979 | ||
| Collaboration to Accelerate Proteogenomics Cancer Care: The Department of Veterans Affairs, Department of Defense, and the National Cancer Institute's Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) Network | Q30238490 | ||
| Assessing the clinical utility of cancer genomic and proteomic data across tumor types. | Q30487077 | ||
| Proteome Profiling Outperforms Transcriptome Profiling for Coexpression Based Gene Function Prediction | Q30834140 | ||
| Open source system for analyzing, validating, and storing protein identification data | Q30978337 | ||
| No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing: Show Me the Data | Q31077059 | ||
| National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures | Q33318292 | ||
| Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry | Q33370510 | ||
| A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice | Q33577844 | ||
| Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies | Q33594636 | ||
| Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective | Q33669587 | ||
| Automated screening of monoclonal antibodies for SISCAPA assays using a magnetic bead processor and liquid chromatography-selected reaction monitoring-mass spectrometry | Q33731947 | ||
| Proteogenomic convergence for understanding cancer pathways and networks | Q33792433 | ||
| Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma | Q33794491 | ||
| Proteogenomic integration reveals therapeutic targets in breast cancer xenografts | Q37736390 | ||
| Antiquated tests within the clinical pathology laboratory | Q37830661 | ||
| Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present | Q38024637 | ||
| Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society | Q33850616 | ||
| Detecting protein variants by mass spectrometry: a comprehensive study in cancer cell-lines | Q33913055 | ||
| CPTAC Assay Portal: a repository of targeted proteomic assays | Q33960135 | ||
| Regulation of alternative splicing by histone modifications | Q34035543 | ||
| Protein identification using customized protein sequence databases derived from RNA-Seq data | Q34079606 | ||
| Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin | Q34123261 | ||
| Panorama: a targeted proteomics knowledge base | Q34141681 | ||
| PASSEL: the PeptideAtlas SRMexperiment library | Q34154235 | ||
| The evolving role of mass spectrometry in cancer biomarker discovery | Q34215422 | ||
| Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics | Q34292436 | ||
| Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics | Q34333925 | ||
| An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer. | Q34503941 | ||
| Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics | Q34654305 | ||
| Isobaric labeling-based relative quantification in shotgun proteomics | Q34669427 | ||
| Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry | Q34751690 | ||
| Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Q34788858 | ||
| From lost in translation to paradise found: enabling protein biomarker method transfer by mass spectrometry | Q35044673 | ||
| Using PeptideAtlas, SRMAtlas, and PASSEL: Comprehensive Resources for Discovery and Targeted Proteomics | Q35090832 | ||
| Sensitive targeted quantification of ERK phosphorylation dynamics and stoichiometry in human cells without affinity enrichment | Q35193821 | ||
| Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic | Q35251561 | ||
| Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification | Q35264312 | ||
| Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. | Q35453691 | ||
| Clinical trials in the era of personalized oncology | Q35555963 | ||
| A targeted proteomics-based pipeline for verification of biomarkers in plasma | Q35596338 | ||
| An extensive library of surrogate peptides for all human proteins. | Q35732540 | ||
| Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks | Q35749545 | ||
| Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers | Q35751680 | ||
| Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes | Q35916507 | ||
| Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry Enables Multiplex, Quantitative Pharmacodynamic Studies of Phospho-Signaling. | Q35926217 | ||
| Reduced-representation Phosphosignatures Measured by Quantitative Targeted MS Capture Cellular States and Enable Large-scale Comparison of Drug-induced Phenotypes | Q35935148 | ||
| A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. | Q36006127 | ||
| Precision of multiple reaction monitoring mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue | Q36011667 | ||
| Proteogenomics connects somatic mutations to signalling in breast cancer | Q36037203 | ||
| Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma. | Q36040373 | ||
| Prediction of colorectal cancer diagnosis based on circulating plasma proteins | Q36057583 | ||
| A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing | Q36070730 | ||
| The expanding role of mass spectrometry in metabolite profiling and characterization | Q36277336 | ||
| Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum | Q36280125 | ||
| A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition. | Q36326056 | ||
| A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer | Q36490656 | ||
| Immobilized Metal Affinity Chromatography Coupled to Multiple Reaction Monitoring Enables Reproducible Quantification of Phospho-signaling | Q36539525 | ||
| Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease | Q36602116 | ||
| First Steps toward Harmonization of LC-MS/MS Thyroglobulin Assays | Q36693015 | ||
| Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry | Q36736452 | ||
| Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays | Q36794987 | ||
| Selected reaction monitoring for quantitative proteomics: a tutorial | Q36973024 | ||
| Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer | Q37060938 | ||
| Mass spectrometry based targeted protein quantification: methods and applications | Q37134146 | ||
| Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies | Q37142875 | ||
| High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. | Q37142882 | ||
| Proteogenomics: Integrating Next-Generation Sequencing and Mass Spectrometry to Characterize Human Proteomic Variation | Q37190570 | ||
| Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium | Q37238264 | ||
| Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues | Q37244491 | ||
| Commercially available antibodies can be applied in quantitative multiplexed peptide immunoaffinity enrichment targeted mass spectrometry assays | Q37258824 | ||
| The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry | Q37286989 | ||
| Proficiency testing of immunohistochemical biomarker assays in breast cancer | Q37310941 | ||
| Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges | Q37363395 | ||
| Institutional implementation of clinical tumor profiling on an unselected cancer population | Q37417570 | ||
| Isotope dilution strategies for absolute quantitative proteomics | Q37430586 | ||
| Perspectives of targeted mass spectrometry for protein biomarker verification | Q37481709 | ||
| Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins | Q37580083 | ||
| NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry | Q37597657 | ||
| Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry | Q37618631 | ||
| Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach | Q37623655 | ||
| A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research. | Q37651691 | ||
| Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics | Q37653060 | ||
| Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment | Q37735589 | ||
| Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. | Q39636313 | ||
| Multiple enzymatic digestion for enhanced sequence coverage of proteins in complex proteomic mixtures using capillary LC with ion trap MS/MS. | Q39644537 | ||
| Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures | Q39676562 | ||
| A novel, multiplexed targeted mass spectrometry assay for quantification of complement factor H (CFH) variants and CFH-related proteins 1-5 in human plasma | Q40574092 | ||
| Quantitative performance of internal standard platforms for absolute protein quantification using multiple reaction monitoring-mass spectrometry | Q41155408 | ||
| Deep-Dive Targeted Quantification for Ultrasensitive Analysis of Proteins in Nondepleted Human Blood Plasma/Serum and Tissues. | Q42279966 | ||
| Newfoundland launches judicial inquiry | Q42741593 | ||
| PHOXTRACK-a tool for interpreting comprehensive datasets of post-translational modifications of proteins | Q44997033 | ||
| Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels | Q45300407 | ||
| Improving the precision of quantitative bottom-up proteomics based on stable isotope-labeled proteins | Q46112925 | ||
| Debunking the Delusion That Precision Oncology Is an Illusion | Q46539715 | ||
| CLSI C62-A: A New Standard for Clinical Mass Spectrometry | Q46790495 | ||
| PeptidePicker: a scientific workflow with web interface for selecting appropriate peptides for targeted proteomics experiments. | Q46901204 | ||
| The role of mass spectrometry and proteogenomics in the advancement of HLA epitope prediction | Q47190955 | ||
| Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer | Q47624398 | ||
| Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). | Q47687028 | ||
| Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment | Q47733361 | ||
| Functional precision cancer medicine-moving beyond pure genomics | Q48013156 | ||
| Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers. | Q48244442 | ||
| Onco-proteogenomics: cancer proteomics joins forces with genomics | Q48256898 | ||
| Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. | Q50994940 | ||
| Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma. | Q51064892 | ||
| Automated Microchromatography Enables Multiplexing of Immunoaffinity Enrichment of Peptides to Greater than 150 for Targeted MS-Based Assays. | Q51694268 | ||
| Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. | Q51794765 | ||
| Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. | Q51907503 | ||
| Automated subcellular localization and quantification of protein expression in tissue microarrays. | Q52030096 | ||
| Targeted mass spectrometry enables robust quantification of FANCD2 mono-ubiquitination in response to DNA damage. | Q52335444 | ||
| Novel RNA-Affinity Proteogenomics Dissects Tumor Heterogeneity for Revealing Personalized Markers in Precision Prognosis of Cancer. | Q52675061 | ||
| Discovery of coding regions in the human genome by integrated proteogenomics analysis workflow. | Q52676380 | ||
| Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. | Q52678539 | ||
| A Multiplexed Mass Spectrometry-Based Assay for Robust Quantification of Phosphosignaling in Response to DNA Damage. | Q52688447 | ||
| Nanodroplet processing platform for deep and quantitative proteome profiling of 10-100 mammalian cells. | Q52729778 | ||
| A novel mass spectrometry-based assay for the accurate measurement of thyroglobulin from patient samples containing antithyroglobulin autoantibodies. | Q53109151 | ||
| Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials. | Q53117937 | ||
| Proteomics meets the scientific method. | Q55056925 | ||
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 | ||
| Facile carrier-assisted targeted mass spectrometric approach for proteomic analysis of low numbers of mammalian cells | Q57134955 | ||
| MRMAssayDB: an integrated resource for validated targeted proteomics assays | Q57461496 | ||
| High-Sensitivity LC-MS/MS Quantification of Peptides and Proteins in Complex Biological Samples: The Impact of Enzymatic Digestion and Internal Standard Selection on Method Performance | Q57712914 | ||
| Perspective: The precision-oncology illusion | Q57765633 | ||
| Isotope-labeled Protein Standards | Q58441935 | ||
| Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia. | Q59054299 | ||
| Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer | Q80226703 | ||
| Comparison of a stable isotope labeled (SIL) peptide and an extended SIL peptide as internal standards to track digestion variability of an unstable signature peptide during quantification of a cancer biomarker, human osteopontin, from plasma using | Q85911497 | ||
| Proteogenomics: Opportunities and Caveats | Q87169094 | ||
| Usefulness of a thyroglobulin liquid chromatography-tandem mass spectrometry assay for evaluation of suspected heterophile interference | Q87843062 | ||
| Proteogenomics of Malignant Melanoma Cell Lines: The Effect of Stringency of Exome Data Filtering on Variant Peptide Identification in Shotgun Proteomics | Q88271987 | ||
| BoxCar acquisition method enables single-shot proteomics at a depth of 10,000 proteins in 100 minutes | Q88596869 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 256-268 | |
| P577 | publication date | 2019-04-01 | |
| P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
| P1476 | title | Clinical potential of mass spectrometry-based proteogenomics | |
| P478 | volume | 16 |
| Q96577423 | Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer |
| Q91787445 | Cancer neoantigen prioritization through sensitive and reliable proteogenomics analysis |
| Q92463690 | Clinical proteomics: a driving force for cancer therapeutic target discovery and precision medicine |
| Q92519216 | Development and Optimization of a Miniaturized Western Blot-Based Screening Platform to Identify Regulators of Post-Translational Modifications |
| Q89944200 | Mass Spectrometry-Based Identification of MHC-Associated Peptides |
| Q90624500 | Picoflow Liquid Chromatography-Mass Spectrometry for Ultrasensitive Bottom-Up Proteomics Using 2-μm-i.d. Open Tubular Columns |
| Q64996408 | Protein biomarker discovery is still relevant and has entered a new phase. |
| Q90072530 | Proteomics advances for precision therapy in ovarian cancer |
| Q93082818 | TEX9 and eIF3b functionally synergize to promote the progression of esophageal squamous cell carcinoma |
| Q92987574 | The Human Ovary and Future of Fertility Assessment in the Post-Genome Era |
| Q90002513 | The path of biomolecular mass spectrometry into open research |
Search more.